Loading
BioPharma Credit PLC Stock: price and insider trades · United Kingdom
2 insiders bought €84k of shares over the last 90 days, the latest by Graeme Proudfoot, filed 30 Sept 2026.
Insider Decl.
41
Thresholds
n/a
Buy Volume
€4M
13 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleSapna Shah2 buys
Graeme Proudfoot1 buy
Nigel Reynolds1 buy
Since the insiders bought
- +4.5%Entry US$0.94 · Close 20 Oct 2026 US$0.98
- -13.1%Entry US$0.96 · Close at T+365 US$0.83
- -3.4%Entry US$1.01 · Close at T+365 US$0.98
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate BioPharma Credit PLC Buy (bullish).
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 824 of 26,280 companies
81.7
score / 100
Value83
Quality80
FCF yld8.3%
Earn yld12%
EV/EBITDA·
ROE9.4%
Gross mgn·
Net mgn98%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.98
Analyst consensus
Buy
Income statement
RevenueUS$132.1M
Net incomeUS$129.9M98.4% margin
Valuation
PER (trailing)9.8x
P/Book1.0x
Beta0.18
Balance sheet & cash
Market capUS$1.1B
Free Cash FlowUS$91.1M
Profitability & ownership
ROE9.4%
ROA5.8%
% insiders6.6%
% institutions49.0%
Last declaration on 30 September 2026
Declarations41 total
70,000 shares@ US$0.9880.0062% mcap100.0% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:93f4afce-2e89-402d-9201-a93a94f827fc
Canonical exit: 28 Dec 2026 (T+90)
76 shares@ £0.72130.0000% mcap6.6% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:580cfe33-aeac-4dcd-b987-584ba1ec4792
27,124.8 shares@ US$0.96930.0023% mcap100.0% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:ca272add-0310-4246-b2b9-6c41d9b2f22b
Canonical exit: 29 Oct 2026 (T+90)
◆
Unknown
54 GBP10RNS
75 shares@ £0.716100.0% of flowLondon Stock ExchangeISIN GB00BDGKMY29RNS:9595740
75 shares@ £0.7166.4% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:204283d4-b980-4895-ac50-e9a4e6a77ff0
137 shares@ £0.701311.4% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:c1a0dd3f-04f3-4f9e-bf8b-7631c764d78d
42,500 shares@ £0.9499.2% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:5a6d4338-bffc-4b85-b945-5a4ce2388479
Canonical exit: 23 Jun 2026 (T+90)
62 shares@ £0.69355.0% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:2b33e2c0-0fcc-418a-8dc9-e4db9c21509d
74 shares@ £0.6585.8% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:5778093
75 shares@ £0.65735.9% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:5650694
121 shares@ £0.6910.4% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:5564195
14,448 shares@ £0.69210.3% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:5472054
Canonical exit: 17 Mar 2025 (T+90)
151 shares@ £0.665812.4% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:5415905
65 shares@ £0.70635.6% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:5295668
67 shares@ £0.70245.6% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:5180166
20,000 shares@ £0.71510.5% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:5122239
Canonical exit: 25 Jun 2024 (T+90)
109 shares@ £0.6929.0% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:5118114
126 shares@ £0.724710.9% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:5040895
63 shares@ £0.68485.1% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:4919354
50,000 shares@ £0.83452.4% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:4554586
Canonical exit: 22 Jan 2023 (T+90)
50,000 shares@ £0.83452.4% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:4554585
Canonical exit: 22 Jan 2023 (T+90)
43 shares@ £0.78658.5% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:4359782
44 shares@ £0.73618.3% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:4277174
42 shares@ £0.71367.5% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:4084652
50 shares@ £0.69988.6% of flowLondon Stock Exchange (XLON)ISIN GB00BDGKMY29FCA-NSM:3966177
25 of 41 declarations
About BioPharma Credit PLC
On March 25, 2026, Sapna Shah, a Director of BioPharma Credit PLC, bought EUR 3,453,892, by far the largest of a record of 15 purchases, 14 of them with an amount, worth EUR 4.3 million in total with a median of EUR 47,689. The purchases of March 27, 2017 come next: EUR 276,219 for Jeremy Sillem and EUR 92,073 for Colin Bond, both PDMR (Director). No sale appears in the record.
The company, listed in London and valued at USD 1.1 billion, has 41 filings from 13 filers. Anita Hyman, a person closely associated with a director, files 25, and the record counts 26 grants. Sapna Shah files 3, Rolf Soderstrom, PDMR (Director), 2 purchases, Linda Davey, a person closely associated with Rolf Soderstrom, 2 purchases, and Graeme Proudfoot 1. From March 27 to 31, 2017, 6 filers bought.
Read moreShow less
Volume is higher in 2024 and 2026 (7 filings each) than in 2023 (1). For 10 purchases the stored 90-day return has a median of 4.7%, with 70% of cases positive (recorded past results, not a forecast). The 8 filings of the last twelve months include 3 purchases. Taking the 41 filings with a known delay, publication follows the trade by a median of 1 day.
